Although low-molecular-weight heparins (LMWHs) have largely replaced unfractionated heparin for the treatment of deep vein thrombosis and pulmonary embolism in the general population, sufficiently powered clinical studies on the use of LMWHs in patients with renal impairment are lacking. In this Viewpoint article, Gallieni and colleagues discuss reasons why LMWHs should be used with caution, at present, in patients with chronic kidney disease.
Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease / M.A. Gallieni, M.G. Cozzolino, C.R. Ronga, D. Brancaccio. - In: NATURE CLINICAL PRACTICE NEPHROLOGY. - ISSN 1745-8323. - 4:9(2008 Sep), pp. 488-489.
Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease
M.A. GallieniPrimo
;M.G. CozzolinoSecondo
;C.R. RongaPenultimo
;D. BrancaccioUltimo
2008
Abstract
Although low-molecular-weight heparins (LMWHs) have largely replaced unfractionated heparin for the treatment of deep vein thrombosis and pulmonary embolism in the general population, sufficiently powered clinical studies on the use of LMWHs in patients with renal impairment are lacking. In this Viewpoint article, Gallieni and colleagues discuss reasons why LMWHs should be used with caution, at present, in patients with chronic kidney disease.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
